Global Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 111.1 million in 2017 and is projected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insghts.
Strong product pipeline and launch of cost-effective generic versions of existing drugs by market players is expected to augment the market growth.
Key players in the market are focused on launching cost-effective generic drugs, in order to treat infantile spasm and address the critical unmet needs of patients. For instance, in May 2018, Amneal Pharmaceuticals launched vigabatrin for oral solution USP, which is a generic equivalent for Sabril. This is the second generic vigabatrin product available in the market. Aucta Pharmaceuticals and Upsher-Smith Laboratories, LLC launched vigabatrin for oral solution under the brand name Vigadrone in July 2018, which is another generic version of vigabatrin (Sabril). As of 2018, there were around 5 novel drug candidates in development. 60% of these drugs are in phase III of development, which are expected to enter the market in the near future, thereby offering effective treatment among the fastest growing markets in the world.
Browse 39 Market Data Tables and 29 Figures spread through 150 Pages and in-depth TOC on Infantile Spasm Treatment, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026.
To know the latest trends and insights in the Infant Spasm Treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/infantile-spasm-treatment-market-2453
Key players operating in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in April 2014, Mallinckrodt Pharmaceuticals acquired Questcor, a company involved in contract manufacturing services. Questcor has FDA approved H.P. Acthar Gel, an injectable drug for 19 indications such as infantile spasm.
Key Takeaways of the Infantile Spasm Treatment Market:
- The global infantile spasm treatment market is expected to exhibit a CAGR of 3.1% over the forecast period, owing to increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases
- Among product type, the adrenocorticotropic hormone (ACTH) segment held a dominant position in the infantile spasm treatment market in 2018, owing to low side effects and greater efficacy than other medications
- Among route of administration, parenteral segment held dominant position in the infant spasm treatment market in 2018, as the effective drug adrenocorticotropic hormone (ACTH) is available in parenteral form
- Key players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Anavex Life Sciences Corp., Catalyst Pharmaceuticals, GW Pharmaceuticals plc, and Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics Inc., Etrophin Inc., and Catalystpharma.
Contact Us